Skip to content

Demographic, Clinical, Biological, Treatment Characteristics and Cardiovascular Events of Patients With Heart Failure in Vietnam: a Multicenter Prospective Observational Study

Demographic, Clinical, Biological, Treatment Characteristics and Cardiovascular Events of Patients With Heart Failure in Vietnam: a Multicenter Prospective Observational Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06516562
Acronym
MCR-HF
Enrollment
2500
Registered
2024-07-24
Start date
2023-08-01
Completion date
2028-06-01
Last updated
2024-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Reduced Ejection Fraction

Keywords

Patient registry, Heart failure, Prospective Observational Study, Demographic, Treatment characteristics, Prognosis, MACE

Brief summary

Describe the clinical characteristics, paraclinical features, and treatment during hospitalization, as well as at 1, 3, and 12 months post-discharge, of heart failure patients at selected cardiovascular centers in Vietnam.

Detailed description

Study Design: Prospective cohort study Study Subjects: Patients discharged with a diagnosis of heart failure with reduced or mildly reduced ejection fraction. Inclusion Criteria: * Patients aged 18 years and older * Diagnosed with heart failure at the time of discharge * Have an ejection fraction (based on imaging modalities such as echocardiography or cardiac MRI) recorded closest to the time of discharge, showing a left ventricular ejection fraction of less than 50% Exclusion Criteria: * Patients and their relatives do not have means of communication with healthcare staff (phone, computer, messaging, etc.) * Patients do not reside in Vietnam after discharge Data Collection: * All patients meeting the criteria at the time of discharge during the study period will be continuously included. Information regarding demographic data, clinical presentation, biological markers, and in-hospital treatment characteristics will be collected using standardized data definitions from EuroHeart data standards for heart failure. * Periodically after hospital discharge (e.g., 1 month, 3 months, 12 months post-discharge), patients will be contacted by investigators to gather information on their current status, medications, and any cardiovascular events, including rehospitalizations, death, and current medical treatment. * Data entry will be performed using the REDCap project at the University of Medicine and Pharmacy, Ho Chi Minh City (https://redcap.umc.edu.vn/)

Interventions

Optimal treatment using current National Guidelines for the diagnosis and treatment of chronic heart failure

Sponsors

University Medical Center Ho Chi Minh City (UMC)
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Patients aged 18 years and older * Diagnosed with heart failure at the time of discharge * Have an ejection fraction (based on imaging modalities such as echocardiography or cardiac MRI) recorded closest to the time of discharge, showing a left ventricular ejection fraction of less than 50%

Exclusion criteria

* Patients and their relatives do not have means of communication with healthcare staff (phone, computer, messaging, etc.) * Patients do not reside in Vietnam after discharge

Design outcomes

Primary

MeasureTime frameDescription
All-cause mortality12 monthsDeath from any cause
Heart failure rehospitalization12 monthsPatient rehospitalization due to cardiovascular causes, excluding apparent non-cardiac causes.

Secondary

MeasureTime frameDescription
Major adverse cardiovascular events12 monthsAcute myocardial infarction, stroke or death from any cause
Guideline-directed medical therapy detail12 monthsInformation regarding guideline-directed medical therapy, including medications used and dose titration over time.

Countries

Vietnam

Contacts

Primary ContactHoang Vu Vu, MD, PhD
vu.vh@umc.edu.vn+84908431304
Backup ContactDang Duy Quang Pham, MD, MSc
quang.pdd@umc.edu.vn+84937134599

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026